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Reversal of Neuropathology and Motor Dysfunction
in a Conditional Model of Huntington's Disease
The pathogenesis of the polyQ expansion on htt func-
tion is poorly understood. A loss of function is unlikely,
as heterozygous and homozygous patients with the mu-
Ai Yamamoto,² JoseÂ J. Lucas,²³ and ReneÂ Hen*
Center for Neurobiology and Behavior
Columbia University
tation have similar clinical features (Wexler et al., 1987).New York, New York 10032
Further, MacDonald and colleagues have identified an
individual that showed no abnormal phenotype despite
a 50% reduction in expression of the normal gene prod-
Summary uct due to a deletion in IT15 (Ambrose et al., 1994).
Similarly, mice heterozygous for the htt null mutation do
Neurodegenerative disorders like Huntington's disease not show features of HD, and homozygotes die early in
(HD) are characterized by progressive and putative embryogenesis (Duyao et al., 1995; Nasir et al., 1995;
irreversible clinical and neuropathological symptoms, Zeitlin et al., 1995). A deleterious gain-of-function mech-
including neuronal protein aggregates. Conditional anism is therefore more probable. This is supported by
transgenic models of neurodegenerative diseases the observation that polyQ stretches exceeding similar
therefore could be a powerful means to explore the thresholds are responsible for several neurological dis-
relationship between mutant protein expression and orders including spinobulbar muscular atrophy (SBMA),
progression of the disease. We have created a condi- dentatorubral-pallidoluysian atrophy (DRPLA), and the
tional model of HD by using the tet-regulatable system. spinocerebellar ataxias (SCA) 1, 2, 3, and 7 (Ross, 1997).
Mice expressing a mutated huntingtin fragment dem- These disorders, known as CAG-repeat disorders, share
onstrate neuronal inclusions, characteristic neuropa- many common traits such as a progressive phenotype
thology, and progressive motor dysfunction. Blockade (Gusella and MacDonald, 1996), subcortical and cortical
of expression in symptomatic mice leads to a disap- atrophy (Koshy and Zoghbi, 1997), as well as neuronal
pearance of inclusions and an amelioration of the be- nuclear aggregates (Davies et al., 1997; DiFiglia et al.,
havioral phenotype. We thus demonstrate that a con- 1997; Becher et al., 1998).
tinuous influx of the mutant protein is required to Transgenic mice have been generated to understand
maintain inclusions and symptoms, raising the possi- the pathogenesis of HD. The models vary in the promoter
bility that HD may be reversible. used, the length of the htt protein, and in the length of
the polyQ (Mangiarini et al., 1996; White et al., 1997;
Reddy et al., 1998; Hodgson et al., 1999; Schilling et al.,Introduction
1999; Usdin et al., 1999). Nevertheless, all transgenic
mice that express an abnormal polyQ length demon-Huntington's disease (HD) is an autosomal dominant
strate a progressive HD-like phenotype while transgenicinherited disorder that is progressive (Wexler et al.,
mice with a normal polyQ length do not. The most exten-
1987). Typically, HD manifests in midlife, and death fol-
sively characterized of these models, the Bates R6 lines
lows 10 to 20 years after onset. The disorder is char-
(Mangiarini et al., 1996), reveal that expression of only
acterized by motor disturbances such as chorea and exon 1 containing a polyQ expansion is sufficient to
dystonia, personality changes, and cognitive decline produce mice with essential neuropathological features
(Ambrose et al., 1994). The pathology is restricted to the of HD. Included among these features are a decrease
brain, with atrophy occurring foremost in the striatum in striatal and total brain size (Hansson et al., 1999),
and to a lesser extent in the cortex. Neither a specific changes in neurotransmitter receptor levels (Cha et al.,
treatment nor a cure is yet available. 1998, 1999), and nuclear and cytoplasmic aggregates
HD is caused by an expansion of CAG repeats (Ru- (Davies et al., 1997; Li et al., 1999). These transgenic
binsztein et al., 1994; Gusella and MacDonald, 1996) mice also develop a progressive motor decline including
near the 59 end of the IT15 gene (HDCRG, 1993). IT15 dystonic and choreic-like movements and late-stage hy-
encodes a ubiquitously expressed 350 kDa protein of poactivity (Carter et al., 1999).
unknown function called huntingtin (htt) (Ambrose et al., Despite the insights gained from the HD mouse mod-
1994). The CAG repeats are translated into a polygluta- els, many critical questions remain. Is the cascade of
mine (polyQ) sequence in the N-terminal portion of htt. pathologic events initiated by the mutant protein depen-
While normal individuals possess a polyQ length of 6 dent upon its continuous expression? Can the disease
to 34 repeats, individuals with greater than 40 repeats be treated after onset of neuropathology or motor symp-
develop HD with virtually 100% penetrance. An inverse toms, or is the damage irreversible? Finding the answer
correlation exists between repeat length with the sever- to these questions can have profound implications for
ity of symptoms and age of onset (Persichetti et al., the development of a therapy for HD. We therefore have
1995). created a conditional mouse model of HD using the
tetracycline-responsive gene system. This system allows
expression of a transgene to be turned off with oral
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administration of tetracycline analogs (Furth et al., 1994;columbia.edu).
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and behavioral deficits of HD. More importantly, we
demonstrate that the progression of the HD-like pathol-
ogy is dependent upon continuous expression of the
polyQ-htt. Furthermore, we find that abolishing expres-
sion of the mutant protein not only halts progression of
the disease, but can reverse aggregate formation and
progressive motor decline.
Results
Mouse Design
The tet-regulated system has been used for conditional
expression in eukaryotic cell systems and mice (Furth
et al., 1994; Kistner et al., 1996; Mayford et al., 1996;
Freundlieb et al., 1997). Regulation of the system is
achieved through the tetracycline-regulated transacti-
vator (tTA), a fusion protein between the tet-repressor
binding domain and a VP16 activation domain (Gossen
and Bujard, 1992). This protein binds specifically to the
tetO operator and induces transcription from an adja-
cent CMV minimal promoter. The combination of both
tTA and the tetO elements allows for continual expres-
sion of a given transgene. Tetracycline and its analogs
can bind to tTA. When this happens, tTA is prevented
from binding to tetO and transcription is inhibitted.
We generated transgenic mice carrying the bidirec-
tional tetO responsive promoter (Baron et al., 1995) fol-
lowed by both a chimeric mouse/human exon 1 with
Figure 1. Mouse Model Designa polyQ expansion of 94 repeats in one direction and
(A) Inducible polyQ-htt transgene: The mutant huntingtin peptideb-galactosidase (lacZ) reporter sequences in the other
consists of a chimeric mouse/human exon 1 with a polyQ expansion(Figure 1A). These mice are designated BiTetO. The tTA
of 94 repeats (HD[CAG]94, see Experimental Procedures). BiTetOtransgene used is under the control of the calcium/cal-
will allow for simultaneous regulation of lacZ with a nuclear localiza-
modulin kinase IIa promoter (CamKIIa-tTA line E and B) tion sequence (NLS).
(Mayford et al., 1996). These tTA lines were chosen to (B) The tTA molecule is driven by the CAMKIIa promoter. In its active
form, tTA binds to the BiTetO sequence to drive expression of bothallow for restricted, conditional expression in the CNS,
transgenes. Doxycycline can inhibit expression of the transgeneswith particularly high expression in the forebrain (May-
by binding to tTA, rendering it inactive.ford et al., 1996; Ghavami et al., 1999). When the BiTetO
mice are crossed with CamKIIa-tTA mice, the resulting
was seen in the striatum, septum, cortex, and hippocam-double transgenic progeny (designated HD94) constitu-
pus (Figures 2B and 2C and not shown). Expression alsotively express both transgenes (Figure 1B). This expres-
was found to a lesser extent in amygdala and hypothala-sion, however, can be abolished in the presence of doxy-
mus, while no expression was detected in the cerebel-cycline (dox).
lum (data not shown). The lacZ expression patterns ap-Heterozygote crosses between BiTetO and CamKIIa-
peared similar to those obtained from crosses betweentTA mice did not yield the expected frequency of 25%
the CamKIIa-tTA lines and other tetO reporter linesfor each genotype (wt, BiTetO, tTA, and HD94). The
(Ghavami et al., 1999). Single transgenic BiTetO miceHD94 mice were underrepresented (6%), because of
showed no staining in any region (Figure 2A), thus dem-a perinatal lethality probably due to expression of the
onstrating that the CMV minimal promoters remainedpolyQ-htt. In order to ensure that expression of the
silent in the absence of the tTA protein.polyQ-htt was postnatal, pregnant mice were given dox
Analysis of the expression of polyQ-htt was performed(2 mg/ml) in their drinking water ad libitum beginning at
with an antibody raised against an N-terminal sequenceE15. After birth, the dox solution was removed. The
of htt, which recognizes the native protein as well asprenatal dox administration allowed for a Mendelian dis-
the aggregates characteristic of the mutant protein (Da-tribution of the four genotypes. All mice in this study
vies et al., 1997; Scherzinger et al., 1997). Eight-week-thus received dox from E15 to P0. Crosses with both
old wt (n 5 4), single transgenics BiTetO (n 5 3) andtTA-expressing lines, CamKIIa-tTA line E and B, pro-
CamKIIa-tTA (n 5 3), and double transgenic HD94 (n 5duced similar results.
4) mice were examined. Increased immunoreactivity was
found in HD94 mice in the striatum, cortex, hippocam-
Expression of polyQ-htt pus (Figures 2E and 2F), and all other lacZ-positive re-
LacZ was used to assess the expression pattern and gions (data not shown). Similarly, regions that were lacZ
effectiveness of this conditional system (Figures 2 and negative exhibited no increased staining for the polyQ-
5). In the adult brain of double transgenic HD94 mice htt, as was the case for the wt and single transgenic
controls (Figure 2D).four weeks of age and older, a high level of lacZ staining
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Figure 3. Neuropathology of 18-Week-Old HD94 Mice
Figure 2. LacZ and polyQ-htt Expression Neuropathological changes were evident in brains of double trans-
genic HD 94 mice (B, D, F, and H) versus single transgenic BiTetO(A±C) LacZ expression was determined in coronal brain sections.
control mice (A, C, E, and G). For quantification, see Figure 6.Tissue was counterstained with fast red. (A) BiTetO single transgenic
(A and B) Nissl staining revealed a decrease in total brain and striatalcontrols were negative for lacZ. (B and C) HD94 mice demonstrated
size, and an increase in ventricular size for HD94 mice.lacZ positive staining in striatum and cortex (B) and the hippocam-
(C and D) Enlargement of the area indicated by the arrows in (A)pus (C).
and (B). The ventricular zone is narrower in HD94 mice (double-(D±F) Sections serial to those stained for lacZ were examined for
headed arrow).polyQ-htt expression using an antibody raised against an N-terminal
(E and F) Reactive astrocytosis in the striatum of HD94 mice ashtt (Davies et al., 1997). (D) BiTetO sections were not immunopositive
indicated by GFAP staining. (F) Reactive astrocytes with the charac-for polyQ-htt (E and F) HD94 brains showed polyQ-htt immunoreac-
teristic hypertrophied star-like shape. (E) GFAP-positive cells intivity in all regions positive for lacZ expression, such as the cell
BiTetO control mice were less abundant and were not reactive.layer of the hippocamus (C and F), but not in those regions that
(G and H) D1 receptor levels were detected using radioligand bindingwere negative.
with [3H]-SCH23380. Images are presented in inverted gray-scale.(G±J) Nuclear and extranuclear staining for polyQ-htt was deter-
(H) HD94 mice had significantly lower receptor levels. The differencemined using an N-terminal htt antibody. Sections were counter-
was greater in the medial striatum than the lateral striatum.stained with cresyl violet to visualize nuclei. (G) No specific staining
Scale bar: (A and B) 1 mm; (C and D) 500 mm; (E and F) 500 mm.was detected in striatum from BiTetO single transgenic control sec-
tions. (H and J) Specific staining in the striatum of double transgenic
HD94 mice was mostly diffuse and nuclear (sharp arrowhead), with
distinct nuclear aggregates of various sizes (short arrowhead and aggregates resembled neuritic staining and appeared
J), and few extranuclear aggregates (open arrowhead). (I) Staining singly or in multiples much like a string of beads (Figure
in the cortex of HD94 mice demonstrated a higher degree of extranu-
2I, open arrow). Staining with an antibody raised againstclear, neuritic-like staining (open arrowhead).
ubiquitin revealed a similar pattern, although the diffuseScale bars: (A±C) 1 mm; (D±F) 500 mm; (G±I) 100 mm; (J) 50 mm.
intranuclear staining was less prevalent (data not shown).
Higher magnification revealed that the majority of stri-
Neuropathology in HD94 Miceatal cells displayed immunoreactivity (Figures 2G, 2H,
We analyzed neuropathological changes apart from ag-and 2J). The most common immunoreactive pattern was
gregates (Figure 3, for quantitative results see Figure 6).a diffuse nuclear staining (Figure 2H, sharp arrow). Nu-
Upon examination of coronal sections of the brains in 18-clear aggregates of different sizes (Figures 2H, blunt
week-old HD94 mice, two differences were immediatelyarrow; and 2J) and, to a lesser extent, extranuclear ag-
apparent. First, the HD94 brains were smaller than theirgregates (Figure 2H, open arrow) were also found. The
age-matched controls (Figures 3A and 3B). Second, aimmunoreacitivity seen in the cortex was similar to the
decrease in striatal size accompanied by a gross en-striatum. However, the occurrence of extranuclear ag-
gregates was much more frequent (Figure 2I). These largement of the ventricles was evident. Nissl staining
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Figure 4. Progressive Clasping Phenotype of
HD94 Mice
Mice were observed during a 15 s tail suspen-
sion test to monitor the progression of the
clasping phenotype between 3 and 40 weeks
of age. Mice were analyzed for (A) clasping
score and (B) clasping duration (represented
in percent control). Control mice represent a
pool of BiTetO, tTA and wt genotypes. No
difference was detected between these three
genotypes. (C and E) 40-week-old BiTetO
mouse during the tail suspension test, and (D
and F) an age-matched HD94 mouse dis-
playing a characteristic full body clasp.
revealed that the ventricular zone of the striatum was short bursts. Both score and duration of the clasping
increased over time. As early as 28 weeks, mice begannoticeably narrower (Figures 3C and 3D).
Reactive astrocytosis in the striatum was also evident to show a full body clasp. By 40 weeks, all mice immedi-
ately assumed a full body clasp and maintained this forin the HD94 mice. Staining with antibodies raised against
glial fibrillary acid protein (GFAP) revealed a higher inci- the entire duration of the test (Figures 4D and 4F). In
many cases, the posture was not immediately releaseddence of staining in the striatum than in control mice.
These astrocytes were clearly reactive (Figure 3F) and when the mice were returned to their cage.
In addition to clasping, at 20 weeks HD94 mice beganwere hypertrophied with the characteristic star-like
shape. The number of reactive astrocytes increased to show a mild tremor that developed into a jerking
motion in some, but not all, mice. Onset of tremor wasover time in HD94 mice, and the gliosis spread through-
out the lateral and medial striatum. In contrast, only very accompanied by decreased grooming, and the fur of
older HD94 mice appeared unkempt (Figure 4F). BiTetOsmall GFAP-positive astrocytes were seen in control
brains (Figure 3E). These positive cells were nonreactive single transgenic mice were indistinguishable from wt
and did not exhibit the clasping or tremor phenotypes.astrocytes, because the GFAP staining was not as ro-
bust as the reactive hypertrophied astrocytes observed In other assessments, HD94 animals did not greatly
differ from their control littermates. Testing in the open-in HD94 brains (Ridet et al., 1997).
A decrease in D1 receptors has been described in HD field paradigm at 8 weeks demonstrated no difference
in total locomotion (data not shown). Nonetheless, bypatients (Turjanski et al., 1995). We therefore assessed
the levels of these dopamine receptors using an autora- 36 weeks, HD94 mice were clearly hypoactive, and re-
mained so until death. Adult HD94 mice were fertile, butdiographic binding assay with [3H]-SCH 23969. D1 re-
ceptor levels were significantly decreased in the stria- as the clasping and tremor worsened, the frequency of
mating by males decreased. No atrophy or deformationtum of HD94 mice (Figure 3H). This decrease was not
uniform, manifesting more severely from medial striatum was evident in the testes of 32-week-old mice. Finally,
although the average life span of double transgenicsto lateral.
was similar to that of wt (2 years), a small number of
HD94 mice died earlier (8 to 10 months). These miceBehavioral Phenotype
HD is characterized by a progressive motor dysfunction appeared to have died by sustaining severe injuries from
fighting with littermates.with choreic and dystonic movements, and parkinson-
ism. The most common dysfunction demonstrated in
the available genetic models is a progressive clasping Evolution of Neuropathology and Behavior
after Turning off polyQ-htt Expressionof the limbs, which is triggered by a tail suspension test
(Mangiarini et al., 1996; Reddy et al., 1998; Carter et al., To analyze the evolution of the phenotype in the absence
of polyQ-htt, transgene expression was turned off with1999; Schilling et al., 1999). Mice were suspended by
the tail for 15 s every 2 weeks between the ages of 3 doxycycline (dox). Dox treatment began at 18 weeks,
an age at which the neuropathology and motor behaviorand 40 weeks. An abnormal movement was scored
when the mouse moved its hindlimbs, forelimbs, or trunk disruption were evident. Mice were split into two groups.
The ªgene-onº group was allowed to develop withoutin a dystonic fashion. Both the score and duration of
the abnormal movement were recorded (Figures 4A and intervention, and the ªgene-offº group was treated with
2 mg/ml of dox in their drinking water (Figure 5G). Treat-4B). Until 4 weeks of age, double transgenic HD94 mice
were indistinguishable from control littermates in this ment was maintained for 16 weeks.
LacZ staining revealed that the dox regimen com-test. At 4 weeks, some HD94 mice began to clasp, and
by 8 weeks all were clasping. At onset, the phenotype pletely abolished expression of the transgene (Figures
5A and 5B). Tissue sections were next examined for httinvolved only the hindlimbs, which were curled into the
body in a dystonic fashion and held and released in and the percentage of neurons positive for nuclear htt
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Figure 6. The Effect of a 16 Week ªGene-Offº Period on the Neuro-
pathological Phenotype of HD94 Mice
Brains of 18-week-old HD94 mice were compared with 34-week-old
gene-on and 34-week-old gene-off HD94 mice. Repeated-measures
ANOVA was conducted across matched sections from brains from
each group. Single transgenic and wt mice at age 18 weeks and 34
weeks did not significantly differ in any of the measurements, and
have thus been pooled as control.
(A) Area of caudate putamen; main effect of group F(3,8) 5 9.666; P ,
0.005.
Figure 5. LacZ and htt Aggregate Staining after 16 Week ªGene- (B) Counts for GFAP-positive reactive astrocytes; main effect of
Offº Period group F(3,6) 5 14.330; P , 0.005.
(C) D1 receptor binding levels are expressed in percent control mean18-week-old HD94 mice were given either 2 mg/ml dox (ªgene-offº)
density; main effect of group F(3,8) 5 56.515; P , 0.005.or vehicle (ªgene-onº) for 16 weeks (see G for schematic). (A and
Significant differences (Fisher post-hoc) between one HD94 groupB) LacZ expression was abolished in gene-off HD94 mice and main-
and control are marked by ª²º: ², P , 0.05; ²²², P , 0.005; andtained in age-matched HD94 gene-on mice.
from ªgene-offº (34 weeks) are marked by * : *, P , 0.05; **, P ,(C and D) Images show cortex and striatum as seen in Figure 2.
0.001; ***, P , 0.005.Immunostaining for htt also was drastically reduced in gene-off
mice. (C) Immunopositive staining is present in the cortex and stria-
tum of gene-on mice. (D) In age-matched gene-off mice, the staining
in the striatum was undetectable, while staining in the cortex was seen in the cortex, though to a lesser extent. Further
confined to scattered cells.
analysis of the striatal tissue at higher magnification(E and F) Higher magnification of the striatum counterstained with
revealed that not only diffuse nuclear staining was re-cresyl violet revealed that the lack of immunoreactivity in gene-off
versed, but both intra- and extranuclear aggregates dis-mice corresponds to a disappearance of both intra- and extranu-
clear aggregates. appeared. The remaining cortical staining corresponded
Scale bars: (A±D) 500 mm; (E and F) 100 mm. to fewer diffuse nuclear stainings and small extranuclear
aggregates (data not shown).
A quantitative neuopathological determination re-
vealed a clear arrest of neuropathology in the gene-offwas assessed. At 18 weeks, 39.9% of the striatal neu-
rons were positive for nuclear htt while at 34 weeks, the mice. Compared to controls, striatal area was signifi-
cantly smaller in 18-week-old HD94 mice and showedvalue increased to 60.0%. In sharp contrast to the gene-
on HD94 mice, less than 1% of the striatal neurons a further significant decrease at 34 weeks (Figure 6A).
On the other hand, gene-off mice did not show furtherfrom the gene-off HD94 mice demonstrated nuclear htt
(Figures 5C and 5D). A similarly drastic reduction was reduction in striatal size while treated with dox. At 34
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weeks, the striatal size of these gene-off mice was signif-
icantly larger than the striatal size of 34 week gene-on
mice, and not significantly different from 18-week-old
mice. GFAP-positive astrocytes were also counted (Fig-
ure 6B). While the number of reactive astrocytes in-
creased in the gene-on HD94 mice, the number signifi-
cantly decreased in the gene-off mice. As a result, the
number of astrocytes in the gene-off mice was interme-
diate between 18-week-old HD94 mice and control.
A change in the D1 receptor level was also seen. By
18 weeks, D1 receptor levels were significantly lower in
HD94 than in control animals, and the levels continued
to decrease over time (Figure 6C). Shutting off expres-
sion of the polyQ-htt halted this progressive loss. The
receptor levels in the gene-off HD94 mice were higher
than the age-matched gene-on HD94 mice, but did not
significantly differ from the levels obtained in 18-week-
old HD94 brains.
Reversal of the Motor Dysfunction
Shutting off expression of the mutant transgene pro-
duced significant changes in the neuropathological phe-
notype of the HD94 mice. We therefore examined the
progressive clasping phenotype in mice after the gene-
Figure 7. Inhibiting Expression of polyQ-htt Allows for Ameliorationoff period. Naive mice were assessed for clasping at 18 of the Clasping Phenotype
weeks. They were then split into a gene-on group and
Naive 18-week-old HD94 mice were assessed in the tail suspension
a gene-off group (receiving water and dox treatment, test and then retested after a treatment of either 2 mg/ml dox (ªgene-
respectively). At 34 weeks, these mice were reassessed offº) or vehicle (ªgene-onº) for 16 weeks.
for clasping (Figure 7). (A) Average score per 15 s test. Repeated-measures ANOVA con-
firmed an interaction between clasping score and age P , 0.05,In the gene-on group, there was an increase in the
F(1,6) 5 11.571. Post-hoc Fisher analysis revealed that in the gene-score for clasping and a significant increase in the dura-
off group, the HD94 34-week-old mice scored significantly lowertion of clasping when expression of the polyQ-htt was
than the HD94 18-week-old mice (*, P , 0.05).
maintained between 18 and 34 weeks. In contrast, the (B) Percent of total test time spent in clasp. Repeated-measures
gene-off group showed a significant decrease in both ANOVA confirmed an interaction between clasping duration and
the score and duration of clasping movements. The age, P , 0.005, F(1,6) 5 25.165. Post-hoc Fisher analysis revealed that
in the gene-on group, HD94 34-week-old mice scored significantlyscore for clasping reversed to a level comparable to
higher than HD94 18-week-old, while in the gene-off group, HD94double transgenics at 8 weeks of age, while the duration
34-week-old scored significantly lower than HD94 18-week-old (*,of clasping reversed to levels similar to that of control
P , 0.05).
mice. The dox treatment did not affect the single trans-
genic control mice (data not shown).
(Alves-Rodrigues et al., 1998), selective reactive astro-
cytosis in the striatum (Hedreen and Folstein, 1995), andDiscussion
a decrease in D1 receptor levels (Turjanski et al., 1995;
Augood et al., 1997). Also, as in HD patients, most of theUsing the tetracycline-responsive gene system, we have
created a conditional mouse model of a neurodegenera- pathological characteristics increased in severity over
time. The phenotype of these mice confirm previoustive disorder. We found that suppression of polyQ-htt
between the ages of 18 and 34 weeks either halted or findings that full-length htt is not necessary to recapitu-
late key characteristics of HD (Mangiarini et al., 1996;reversed the different aspects of the HD-like phenotype
in the HD94 mice. Specifically, the nuclear and cyto- Vonsattel and DiFiglia, 1998; Carter et al., 1999; Schilling
et al., 1999).plasmic aggregates disappeared, the number of reac-
tive astrocytes decreased, and the progressive striatal The progressive striatal atrophy in HD patients has
been mainly attributed to neuronal loss and has beenatrophy and decrease in D1 receptor levels halted. Fur-
thermore, stopping expression of the polyQ-htt not only associated with the occurrence of reactive astrocytosis
(Vonsattel et al., 1985; Myers et al., 1991). In the striatumprevented the worsening of the clasping phenotype, but
also ameliorated it to levels approaching the control. of our HD94 mice, there is a clear indication of selective
reactive astrocytosis. However, preliminary cell densityExpression of polyQ-htt under the control of a fore-
brain-specific promoter was sufficient to create a mouse measurements have revealed that despite a 25% de-
crease of the striatal area, no significant difference inmodel of Huntington's disease (HD94). The phenotype of
these mice is consistent with HD patients: an abnormal neuron number between control striata (n 5 2 brains,
7253.75 6 303.35 neurons/mm2) and 18 week HD94 stri-motor phenotype (Martin and Gusella, 1986), a decrease
in striatal size (Aylward et al., 1994; Backman et al., 1997; ata (n 5 2 brains, 7347.00 6 690.90 neurons/mm2) can
be demonstrated. Well-correlated with this finding is theHalliday et al., 1998), intra- and extranuclear aggregates
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very limited number of TUNEL-positive stainings seen expression of the polyQ-htt. When expression is discon-
in the HD94 mice. An explanation for the reduction in tinued, this toxic insult also ceases. It is at this point
striatal area may be found in the R6 transgenic lines. In that the brain can recover some of its functions, which
both the R6/1 and R6/2 mice, a decrease in striatal is attested to by the amelioration of the clasping pheno-
volume without a change in cell number has been re- type. Preliminary studies on the rotarod further support
ported (Mangiarini et al., 1996; Hansson et al., 1999). recovery. Although 18-week-old gene-on HD94 mice
To account for the volumetric decrease, Hansson et al. were significantly impaired at this task and failed to
hypothesized that the change in volume can be attrib- maintain their balance, gene-off HD94 mice regained
uted to a reduction in either cell size or in extracellular their ability to maintain their balance on the rotarod and
matrix. In the HD94 mice, it is possible that similar mech- were indistinguishable from control. We are currently
anisms are applicable. investigating potential physiologic changes that may un-
Our main intent was to determine if constant expres- derlie recovery by using cellular recording and more
sion of the polyQ-htt is necessary for the progression global measurements, such as 2-deoxyglucose and PET
of the various phenotypes. We therefore shut down ex- scans, before and after turning gene expression off.
pression of the transgene at an age when HD94 mice One of the most puzzling characteristics of HD is the
clearly displayed the pathologic phenotype. One of the striatal-specific atrophy despite widespread expression
most dramatic changes seen in the gene-off mice was of htt. Two of the most common explanations are that
the disappearance of the aggregates. Biochemical anal- either the striatum itself is particularly vulnerable to the
ysis had indicated that the aggregates were extremely expression of polyQ-htt, or the cortex is vulnerable to
stable structures (Davies et al., 1999; Kazantsev et al., the polyQ-htt and then exerts a detrimental effect on
1999). Our results show that despite the difficulty in the striatum. We have shown here that expression of
biochemically dissolving or denaturing them, the neu- polyQ-htt in the forebrain is sufficient to recapitulate key
rons are capable of dispelling the nuclear and extranu- neuropathological features of HD. To further explore
clear accumulation of htt. Our results suggest that the
the spatial relationship between expression of polyQ-
ubiquitinated aggregates are neither inaccessible to the
htt and HD, we will take advantage of the binary natureproteosome, nor an indication that the proteolytic path-
of the system we have employed to create the HD94ways are fully or irreversibly compromised (Lansbury,
mice. We are currently expressing polyQ-htt in either1997; Alves-Rodrigues et al., 1998). Our findings also
the striatum or cortex to address this issue.argue against, but do not preclude, models in which
In summary, we have shown that turning off the ex-polyQ-htt is required only to initiate the process of ag-
pression of polyQ-htt at an age when HD94 mice aregregation of other cellular proteins including wild-type
displaying neuropathological and behavioral pheno-htt. (Lansbury, 1997).
types results in either a halt or a reversion of the differentThe second significant finding is the reversion of
phenotypes. This implies that irreversible changes thatthe clasping phenotype. Among the histological mea-
commit the cell to neuronal dysfunction or death havesurements we performed on these animals, only two
not necessarily taken place. Our results therefore sug-demonstrated reversal when the gene was turned off:
gest that therapeutic approaches aimed either to de-aggregate formation and reactive astrocytosis. This cor-
stroy or inactivate the mutant huntingtin protein mightrelation between the disappearance of aggregates and
be effective. Furthermore, the motor recovery indicatesthe amelioration of the clasping phenotype may suggest
that plastic changes can occur when the toxic insultthat the aggregates are responsible for the pathology.
However, it is equally plausible that the aggregates are ceases. The elucidation of the mechanisms responsible
not toxic themselves, but a consequence of the toxicity may provide new targets for therapeutic interventions
of the soluble polyQ-htt. They might therefore act as an for patients suffering from HD and other neurodegenera-
indicator of cellular dysfunction or a means by which tive disorders.
the neurons attempt to protect themselves (Klement et
al., 1998; Saudou et al., 1998). Our experiments do not
distinguish between these scenarios, because by abol- Experimental Procedures
ishing expression of the soluble polyQ-htt, the aggre-
Generation of Injection Fragmentgates also disappeared. However, our results further
The microinjection construct was a 1.1 kb NarI-XhoI fragment thatconfirm that neither soluble nor aggregated polyQ-htt
consists of z100 bp UTR sequences, a chimeric mouse/human exoncauses neurons to die. At the onset of the gene-off
1 with a polyQ expansion of 94 repeats, with an A to G mutation in
experiment, the majority of the neurons displayed nu- the 42nd CAG triplet, and z600 bp of intronic sequence. The chimeric
clear staining. If all of these neurons were to die, a further mouse/human exon 1 fragment was created by replacing a XmnI-
decrease in striatal area would result during the gene- KpnI fragment from a 1.6 kb PstI mouse genomic fragment with an
off period. Instead, this does not occur, and if anything, XmnI-KpnI PCR generated human fragment (received from Drs. S.
Zeitlin and A. Efstradiatis) (Levine et al., 1999). The NarI-XhoI frag-a mild recovery takes place. Consistent with these find-
ment was reoriented by subcloning into ClaI-XhoI of pBSII KS(1)ings are the other mouse models that display nuclear
(Stratagene). Next, a 1 kb PstI-XhoI was cloned into PstI-SalI of astaining and aggregates, but no cell death (Davies et al.,
plasmid containing a bidirectional tetO sequence flanked by cyto-1999; Usdin et al., 1999; Wheeler et al., 1999). Whether or
megalovirus (CMV) minimal promoters with lacZ reporter sequencesnot the polyQ-htt is toxic in an aggregated or soluble
(pBI-3) (Baron et al., 1995). Lastly, a 7.7 kb AseI fragment was mi-
state, we demonstrate that its continuous expression is croinjected into single cell CBAxC57BL/6 embryos. The founder
required for the progression of the pathology. male was crossed with wild-type (wt) CBAxC57BL/6 females. South-
The decrease in reactive astrocytosis indicates that ern analysis of the founder and F1 progeny revealed integration of
one copy of the injection fragment (data not shown).there is a decrease of the toxic insult exerted by the
Cell
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Animals square micrometers by Stereoimager. The measure was then con-
verted to percent control. GFAP and nuclear counts were deter-All experiments were performed on CBAxC57BL/6 inbred mice.
BiTetO, CamKIIa-tTA, HD94, and wt mice were bred at the New mined across four matched striatal sections from three brains per
group. Successive measures were then analyzed by repeated-mea-York State Psychiatric Institute animal facility. Mice were housed
five per cage with food and water available ad libitum. They were sures ANOVA followed by Fisher post-hoc tests.
maintained in a temperature-controlled environment on a 12 hr light/
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